Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Chemotherapy in Newly Diagnosed Standard-Risk B-ALL or Localized B-LLy
NCT01190930Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Aug 2010
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 3 trial of methotrexate, vincristine sulfate liposome injection, dexamethasone in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Children's Oncology Group. Started Aug 2010; status: completed.
02
Drugs
methotrexatevincristine sulfate liposome injectiondexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT01190930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01190930.